Literature DB >> 7684949

Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline.

J T Hsieh1, H C Wu, M E Gleave, A C von Eschenbach, L W Chung.   

Abstract

Prostate-specific antigen (PSA), a M(r) 34,000 serine protease, is recognized as a useful marker for the detection and prognosis of patients with prostate cancer. Although serum PSA is an excellent prognostic indicator, an increasing number of factors were found to regulate the PSA expression of prostatic cancer cells, which include androgenic steroids, the growth factors (GFs) and the extracellular matrix. The purpose of this study is to define a novel protein factor that may be responsible for regulating PSA expression by androgen-independent (AI) human prostate cancer cells. We have established a LNCaP subline (C4) from a parental LNCaP tumor grown in a castrated host. The C4 subline overexpressed PSA mRNA and protein. Serum-free conditioned medium (CM) isolated from the C4 subline is able to stimulate PSA gene expression in parental LNCaP cells in a concentration-dependent manner. This autocrine PSA-inducing activity was found to be organ specific because CMs from other fibroblast cell lines (such as bone, prostate, kidney, and lung fibroblasts) and the CMs from several prostatic carcinoma cell lines (such as parental LNCaP, PC-3, DU-145) and a bladder transitional carcinoma cell line (WH) fail to exhibit similar activity. The activity of the CM from the C4 subline cannot be substituted by GFs such as TGF-alpha, TGF-beta, bFGF, HGF, KGF, or NGF; neuropeptide (bombesin/GRP); secondary messenger analogue (dibutyryl cAMP); beta 2-adrenergic agonist (isoproterenol); or alpha 1-adrenergic agonist (phenylephrine), indicating that the factor(s) may be a novel prostate-specific autocrine factor (PSAF). Both androgen and PSAF exhibit an additive effect on up-regulating PSA gene expression, suggesting that the signal transduction pathway elicited by PSAF may differ from that mediated by the androgen receptor. Further characterization of PSAF by heat, acid, and trypsin digestion revealed that the PSAF may be a protein factor with a unique amino acid composition. These observations suggest that a novel autocrine pathway mediated by PSAF may be responsible for the overexpression of PSA mRNA and protein in a human prostatic cancer cell line. The potential clinical significance of this factor will be discussed.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684949

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

Review 1.  Racial differences in the androgen/androgen receptor pathway in prostate cancer.

Authors:  C A Pettaway
Journal:  J Natl Med Assoc       Date:  1999-12       Impact factor: 1.798

2.  Species-specific fibroblasts required for triggering invasiveness of partially transformed oral keratinocytes.

Authors:  Daniela Elena Costea; Keerthi Kulasekara; Evelyn Neppelberg; Anne Christine Johannessen; Olav Karsten Vintermyr
Journal:  Am J Pathol       Date:  2006-06       Impact factor: 4.307

3.  Production of milligram concentrations of free prostate specific antigen (fPSA) from LNCaP cell culture: difference between fPSA from LNCaP cell and seminal plasma.

Authors:  J T Wu; B W Lyons; G H Liu; L L Wu
Journal:  J Clin Lab Anal       Date:  1998       Impact factor: 2.352

Review 4.  Prostate epithelial differentiation is dictated by its surrounding stroma.

Authors:  L W Chung; R Davies
Journal:  Mol Biol Rep       Date:  1996       Impact factor: 2.316

5.  Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Authors:  Liqun Chen; Salma Siddiqui; Swagata Bose; Benjamin Mooso; Alfredo Asuncion; Roble G Bedolla; Ruth Vinall; Clifford G Tepper; Regina Gandour-Edwards; Xubao Shi; Xiao-Hua Lu; Javed Siddiqui; Arul M Chinnaiyan; Rohit Mehra; Ralph W Devere White; Kermit L Carraway; Paramita M Ghosh
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

6.  Changes in prostate-specific antigen (PSA) level correlate with growth inhibition of prostate cancer cells treated in vitro with a novel anticancer drug, irofulven.

Authors:  A L Woynarowska BAHigdon; R M Muñoz; P Bushong; S J Waters
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

7.  Androgen Receptor regulation of Vitamin D receptor in response of castration-resistant prostate cancer cells to 1α-Hydroxyvitamin D5 - a calcitriol analog.

Authors:  Benjamin Mooso; Anisha Madhav; Sherra Johnson; Mohana Roy; Mary E Moore; Christabel Moy; Grace A Loredo; Rajendra G Mehta; Andrew T M Vaughan; Paramita M Ghosh
Journal:  Genes Cancer       Date:  2010-11-16

8.  Androgen-repressed phenotype in human prostate cancer.

Authors:  H Y Zhau; S M Chang; B Q Chen; Y Wang; H Zhang; C Kao; Q A Sang; S J Pathak; L W Chung
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-24       Impact factor: 11.205

9.  Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes.

Authors:  Z Sun; J Pan; S P Balk
Journal:  Nucleic Acids Res       Date:  1997-08-15       Impact factor: 16.971

10.  Molecular characterization of aromatase inhibitor-resistant, tamoxifen-resistant and LTEDaro cell lines.

Authors:  Selma Masri; Sheryl Phung; Xin Wang; Shiuan Chen
Journal:  J Steroid Biochem Mol Biol       Date:  2009-11-06       Impact factor: 4.292

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.